Relationship between Aldehyde Dehydrogenase, PD-L1 and Tumor-Infiltrating Lymphocytes with Pathologic Response and Survival in Breast Cancer

Flores, M. López; Franco, Emiliano Honrado; Cousido, Luis Felipe Sánchez; Minguito‐Carazo, Carlos; Guadarrama, Oscar Sanz; González, Laura López; Pascual, M. E. Vallejo; Torre, Antonio José Molina de la; Palomo, Andrés García; González, A.

doi:10.3390/cancers14184418

Cited by 1 publication

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, Liu et al previously proposed that high ALDH1A1 expression in tumor tissues could independently predict favorable outcomes in TNBC 39 . Flores et al also reported a correlation between ALDH1A1 expression and pCR 40 . Althobiti et al specifically evaluated ALDH1A1 immunoexpression and found a significant association with poor survival, particularly in the luminal B and TNBC subtypes 41 .…”

Section: Discussionmentioning

confidence: 85%

Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial

Freitas,

Nunes,

Mano

et al. 2023

Sci Rep

View full text Add to dashboard Cite

This exploratory analysis of the Neoadjuvant Carboplatin in Triple Negative Breast Cancer (NACATRINE) study aimed to identify the biomarkers of pathological complete response (pCR) in patients with triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC) within the context of a clinical trial. The NACATRINE trial is a phase II, single-center, randomized, open-label clinical trial that investigated the addition of carboplatin to sequential anthracycline- and taxane-based NAC for TNBC. We evaluated the gene expression in untreated samples to investigate its association with pCR, overall survival (OS), and disease-free survival (DFS). RNA was extracted from the tissue biopsy, and the nCounter Breast Cancer panel was used to analyze gene expression. Of the 66 patients included in the gene expression profiling analysis, 24 (36.4%) achieved pCR and 42 (63.6%) had residual disease. In unsupervised hierarchical clustering analyses, differentially expressed genes between patients with and without pCR were identified irrespective of the treatment (24 genes), carboplatin (37 genes), and non-carboplatin (27 genes) arms. In receiver operating characteristic (ROC) curve analysis, 10 genes in the carboplatin arm (area under the ROC curve [AUC], 0.936) and three genes in the non-carboplatin arm (AUC, 0.939) were considered to be potential pCR-associated biomarkers. We identified genes that were associated with improvements in OS and DFS in addition to being related to pCR. We successfully identified gene expression signatures associated with pCR in pretreatment samples of patients with TNBC treated with NAC. Further investigation of these biomarkers is warranted.

show abstract

Section: Discussionmentioning

confidence: 85%